Premium
Five‐year results of a modified left atrial maze IV procedure in the treatment of atrial fibrillation: a randomized study
Author(s) -
Zhang Dengshen,
Shi Jun,
Quan Huayan,
Liu Lu,
Zhang Jian,
Guo Yingqiang
Publication year - 2020
Publication title -
anz journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.426
H-Index - 70
eISSN - 1445-2197
pISSN - 1445-1433
DOI - 10.1111/ans.15486
Subject(s) - medicine , atrial fibrillation , hazard ratio , confidence interval , randomized controlled trial , ablation , radiofrequency ablation , adverse effect , cardiology , surgery , anesthesia
Background The left atrial maze IV (LAM‐IV) alone has been used to eliminate atrial fibrillation (AF) without severe right heart diseases. However, we felt that it could be improved and developed a modified LAM‐IV (MLAM‐IV). In this prospective trial, we aimed to investigate 5‐year clinical outcomes of AF in patients treated by the novel MLAM‐IV technique. Methods Between September 2012 and October 2013, 120 patients who underwent valve surgery and bipolar radiofrequency ablation for AF were randomized into the LAM‐IV group ( n = 60) or MLAM‐IV group ( n = 60). At postoperative follow‐up examinations, data were recorded at 1, 3 and 6 months, and annually thereafter. Results The mean ablation time and postoperative ventilation time were shorter in the MLAM‐IV group than in the LAM‐IV group ( P < 0.001 and P = 0.03, respectively). At 5 years, the rate of freedom from AF was 69.0% in the MLAM‐IV group and 60.0% in the LAM‐IV group (hazard ratio 0.71, 95% confidence interval 0.39 to 1.32, P = 0.42). There were no differences with respect to the early operative mortality and major complications, late mortality, and major adverse events. Conclusions The MLAM‐IV provides a technically simpler ablation process. The MLAM‐IV was associated with less ventilation support in the early postoperative period. The long‐term efficacy of the MLAM‐IV in the treatment of AF is comparable to that of the LAM‐IV.